Dr. Peter Marks, a pivotal figure within the Food and Drug Administration (FDA), has announced his resignation amidst controversy over vaccine misinformation. Marks, who has been at the helm of the FDA’s Center for Biologics Evaluation and Research for nearly a decade, stepped down citing what he termed as “misinformation and lies” surrounding immunization from Health and Human Services Secretary Robert F. Kennedy Jr. This development was confirmed by a resignation letter acquired by CNBC.
Marks’ role was crucial in the evaluation of COVID-19 vaccines, setting up guidelines for groundbreaking treatments such as cell and gene therapies. As one of the leading vaccine regulators at the FDA, his resignation sends ripples through the biotech industry, already navigating challenging waters over recent years. According to The Wall Street Journal, Marks was reportedly given the choice to resign or face termination by an official from the Department of Health and Human Services. However, none of the involved parties, including Marks, the FDA, or the Department of Health and Human Services, have provided immediate comments on the matter.
In his letter addressed to the acting FDA Commissioner Sara Brenner, Marks commended the agency’s staff for their exceptional work in fast-tracking vaccines that met the stringent standards of quality, safety, and effectiveness expected by the public. He acknowledged that such achievements have significantly curtailed COVID-19 morbidity and mortality in the U.S. and globally. However, Marks expressed deep concern regarding the growing narrative around the adverse health effects of immunization, pointing to the recent measles outbreak as a glaring example of the perils of undermining confidence in vaccines.
“As you are aware, I was willing to work to address the Secretary’s concerns regarding vaccine safety and transparency by hearing from the public and implementing a variety of different public meetings and engagements with the National Academy of Sciences, Engineering, and Medicine,” Marks stated in his resignation letter. He went on to lament that “truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies.”
Well-respected in the biopharma sector, Marks frequently participated in conferences advocating for accelerated development of innovative therapies, with a special focus on rare diseases. His exit could potentially unsettle an already shaky biotech industry. Just last fall, while speaking remotely at the Jefferies London Healthcare Conference, Marks affirmed his commitment to stay as long as he was welcome, emphasizing the importance of steady leadership within the FDA. “I will stay around as long as I’m considered to be welcome to stay around,” he remarked in comments reported by Endpoints News. “I think it’s very important that people see that there’s constant leadership here — that we are here to work with either side of the aisle.”
In an era where public confidence in vaccines is paramount, the implications of Marks’ resignation resonate beyond the walls of the FDA, highlighting the ongoing tug-of-war over facts and misinformation in public health discourse. Marks’ departure underscores significant tensions within health governance and the urgent need for a collective commitment to science and transparency in public health.
Original Source: https://www.cnbc.com/2025/03/28/fda-vaccine-official-peter-marks-resigns-in-opposition-to-rfk-jr-.html
Category :
Tags:
Publish Date: 2025-03-29 09:09:00
